Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026

Autonomix Medical (NASDAQ: AMIX) will present new long-term clinical data on a transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at ECIO 2026 in Basel, April 26–30, 2026.

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) will present new long-term clinical data on a transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at ECIO 2026 in Basel, April 26–30, 2026.

The oral presentation (Abstract No. 350) titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation” will be delivered by Nikola Cesarovic, PhD, on April 29, 2026, 8:30–10:00 AM (Europe/Zurich), highlighting long-term outcomes from the company’s ongoing clinical evaluation of its minimally invasive, transvascular RF energy-based approach.

Argus Apr 22 session

-2.25% close to close Open Argus

Details

News Market Reaction – AMIX

On Apr 22, the day this news came out, AMIX closed 2.25% below the previous close.

Data tracked by StockTitan Argus for the Apr 22 session.

Key Figures

Conference dates: April 26–30, 2026 Abstract number: Abstract No. 350 Presentation date: April 29, 2026 +1 more

Conference dates

April 26–30, 2026

ECIO 2026 meeting dates in Basel

Abstract number

Abstract No. 350

Oral presentation on pancreatic adenocarcinoma pain mitigation

Presentation date

April 29, 2026

Scheduled ECIO oral presentation by Nikola Cesarovic, PhD

Presentation time

8:30 AM–10:00 AM

Europe/Zurich session window for ECIO oral presentation

Historical Context

5 past events · Latest: Apr 08

5 events

1. Apr 08

   Conference selection

   24h Move

   +4.5%

   Featured abstract and podium presentation for long-term pancreatic cancer pain data at SIR 2026.

2. Mar 11

   Investor conference slot

   24h Move

   +0.3%

   Management presenting at LSI USA ’26 with investor meetings, enhancing institutional visibility.

3. Mar 05

   Innovation competition

   24h Move

   +2.2%

   Selection for CRT 2026 Best Innovation Competition highlighting transvascular nerve-targeted technology.

4. Mar 04

   Clinical podium data

   24h Move

   +3.1%

   Top Abstract at CRT 2026 for clinical feasibility and outcomes of transvascular RF nerve neurolysis.

5. Feb 25

   Strategic update

   24h Move

   +8.0%

   CEO Corner segment outlining publication strategy and push for peer-reviewed validation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

transvascular radiofrequency (rf) ablation, pancreatic adenocarcinoma, denervation, rf energy-based ablation, +2 more

6 terms

transvascular radiofrequency (rf) ablation medical

"evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation"

A minimally invasive medical procedure that sends controlled radiofrequency energy through a thin tube inserted into a blood vessel to heat and destroy targeted tissue, such as small tumors or abnormal heart tissue. Think of it like guiding a focused, tiny hot wire to a precise spot inside the body to remove a problem without open surgery. Investors care because adoption affects demand for specialized devices, hospital capital spending, clinical outcomes, and reimbursement trends, all of which influence market size and revenue potential.

pancreatic adenocarcinoma medical

"Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation"

Pancreatic adenocarcinoma is a type of cancer that starts in the cells of the pancreas, the organ that helps digestion and controls blood sugar. It matters to investors because it is often aggressive and hard to detect early, so progress or setbacks in diagnostics, drugs or clinical trials can strongly affect the value of companies working on treatments—similar to how a breakthrough or failure in fixing a critical bridge can change the fortunes of contractors and insurers.

denervation medical

"a long-term analysis of denervation via transvascular RF energy-based ablation"

Denervation is the loss or deliberate interruption of nerve signals to a specific organ or tissue, often achieved by cutting, destroying, or blocking nerves. Like unplugging a lamp to stop it from turning on, denervation is used as a medical approach to reduce unwanted activity such as high blood pressure or chronic pain; for investors it matters because devices and drugs that perform or affect denervation can drive clinical outcomes, regulatory decisions, safety profiles, and market opportunities.

rf energy-based ablation medical

"denervation via transvascular RF energy-based ablation"

A medical procedure that uses controlled radiofrequency (RF) electrical energy to heat and destroy targeted tissue, such as tumors, abnormal heart pathways, or nerves causing pain. Investors care because RF ablation devices, disposable probes, and related services drive sales, regulatory review, and reimbursement decisions; adoption rates and clinical outcomes influence demand much like how a more effective tool can replace older equipment in a workshop.

interventional oncology medical

"European Conference on Interventional Oncology (ECIO) 2026"

Interventional oncology is a branch of medicine that uses image-guided, minimally invasive procedures to treat cancer by targeting tumors directly—through techniques such as precise heat, cold, chemical delivery, or blocking a tumor's blood supply. Investors care because it drives demand for specialized devices, hospital services and repeatable outpatient procedures, and can change treatment costs and patient outcomes much like a targeted tool that removes a weed without digging up the whole garden.

oral presentation technical

"has been accepted as an oral presentation in the session"

A spoken report given to an audience that summarizes facts, results or plans—often delivered at conferences, meetings or investor events. Investors watch oral presentations because they can reveal new data, management plans or interpretations that affect a company’s prospects; like hearing a coach explain a game plan, the tone, detail and emphasis can change expectations and market reactions almost immediately.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

THE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that new long-term clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the European Conference on Interventional Oncology (ECIO) 2026 being held April 26 – 30, 2026 in Basel CH.

The presentation, titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation” (Abstract No. 350), has been accepted as an oral presentation in the session “Y90 and Novel Therapies.”

The presentation will be delivered by Nikola Cesarovic, PhD, on Wednesday, April 29, 2026, from 8:30 AM to 10:00 AM (Europe/Zurich), and will highlight long-term outcomes from the Company’s ongoing clinical evaluation of its minimally invasive, transvascular RF energy-based approach.

Pancreatic cancer is often associated with severe, difficult-to-manage pain, representing a significant unmet medical need. Autonomix’s proprietary technology is designed to selectively target and ablate relevant nerves via the vascular system, with the potential to provide meaningful and durable pain relief while improving patient quality of life.

The ECIO Annual Meeting convenes leading interventional oncologists and healthcare professionals to showcase advances in image-guided cancer therapies and emerging treatment technologies. For more information, please visit ecio.org.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Autonomix Medical (AMIX) present its ECIO 2026 data?

Autonomix will present on April 29, 2026 from 8:30–10:00 AM (Europe/Zurich) in Basel. According to the company, the oral presentation is part of the ECIO session “Y90 and Novel Therapies” and covers long-term clinical outcomes.

What is the title and abstract number of the AMIX ECIO 2026 presentation?

The presentation is titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation” (Abstract No. 350). According to the company, this is accepted as an oral presentation in the Y90 and Novel Therapies session.

Who will present Autonomix’s long-term pain mitigation data at ECIO 2026?

The presentation will be delivered by Nikola Cesarovic, PhD. According to the company, Dr. Cesarovic will highlight long-term outcomes from the ongoing clinical evaluation of the transvascular RF energy-based approach.

What clinical approach will Autonomix (AMIX) discuss at ECIO 2026 for pancreatic cancer pain?

Autonomix will discuss a transvascular radiofrequency (RF) energy-based denervation technique. According to the company, the minimally invasive approach is designed to target nerves via the vascular system for durable pain relief.

How does Autonomix say its technology may benefit pancreatic cancer patients?

The company says the technology aims to provide meaningful and durable pain relief and improved quality of life. According to the company, the transvascular RF approach selectively targets and ablates relevant nerves via the vascular system.